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Abstract
Objectives. This post hoc analysis of the TOZURA study programme evaluated the efficacy and safety of subcutane-
ous tocilizumab (TCZ-SC) as monotherapy or with concomitant conventional synthetic DMARDs (csDMARDs) in patients
with RA categorized by baseline glucocorticoid (GC) use.
Methods. TOZURA was a multinational, open-label, single-arm, common-framework study programme (11 protocols,
22 countries) in patients with moderate to severe RA in whom csDMARDs or biologic therapies had failed or who were
MTX naı¨ve. Patients received once-weekly TCZ-SC 162mg for 524weeks as monotherapy or in combination with
csDMARDs and/or oral GC use (410mg/day prednisone or equivalent), which was to be continued unchanged for
24weeks. Treatment subgroups were defined by baseline GC use and analysed for efficacy and safety.
Results. Of 1804 patients who received TCZ-SC, 145 received monotherapy + GC, 208 received monotherapy without
GC, 730 received combination therapy + GC and 721 received combination therapy without GC. The median GC dose in
both GC subgroups was 5mg/day. The proportion of patients who achieved clinical remission, defined as DAS in 28
joints using ESR <2.6, increased similarly from baseline to week 24 in all subgroups. Improvements in patient-reported
outcomes were similar in all subgroups. Overall adverse event profiles were generally similar between subgroups, with
some slight numerical differences between GC and non-GC subgroups.
Conclusion. The incremental efficacy benefits of TCZ-SC as monotherapy and in combination with csDMARDs were
similar between patients with and without previous and continued oral GC treatment, with generally similar safety profiles.
Trial Registration. ClinicalTrials.gov, http://www.clinicaltrials.gov, NCT01941940, NCT01941095, NCT01951170,
NCT01987479, NCT01988012, NCT01995201, NCT02001987, NCT02011334, NCT02031471, NCT02046603, NCT02046616.
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Rheumatology key messages
. The impact of glucocorticoid use was analysed in RA patients treated with open-label subcutaneous tocilizumab.
. Similar effective disease control with tocilizumab monotherapy or combined with csDMARD, irrespective of
glucocorticoid use.
. Tocilizumab’s safety was similar across glucocorticoid treatment subgroups and consistent with its known profile.
Introduction
RA is a chronic autoimmune disease characterized by sys-
temic inflammation, autoantibodies, persistent synovitis
and joint destruction [1]. RA significantly impacts a pa-
tient’s physical function and reduces quality of life, work
productivity and social participation [2]. Oral glucocorticoid
(GC) therapy is initiated in the majority of patients with RA
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to rapidly control symptoms of pain and inflammation at the
same time that DMARD therapy is initiated [3,4]. In clinical
trials in RA, these patients are generally not excluded from
participation if they are receiving a stable GC dose at base-
line, and they often comprise 40!60% of the study popu-
lation. GC therapy in patients with RA is well known both
for its DMARD effects and for increased risk of its own
adverse events (AEs) [3!5]. Nevertheless, the effect of con-
comitant GCs on the efficacy, patient-reported outcomes
and safety of the biologic DMARDs (bDMARDs) or targeted
conventional synthetic DMARDs (csDMARDs) in a clinical
trial has not been evaluated in detail, except for in a report
on a post hoc pooled analysis of the effects of GC use in
tofacitinib trials [6].
Tocilizumab (TCZ) is a humanized monoclonal antibody
that blocks interleukin 6 signalling and has been approved
worldwide for the treatment of RA as monotherapy and in
combination with csDMARDs [7]. The efficacy and safety
of TCZ was first established in its intravenous formulation
(TCZ-IV) in clinical trials in patients with RA who had an
inadequate response to csDMARDs or anti-TNF agents
[8!12]. The efficacy and safety of the subcutaneous for-
mulation of TCZ (TCZ-SC) was established in the phase 3
SUMMACTA, BREVACTA and MUSASHI trials [13!15].
Each of these trials had a long-term extension of42 years
that demonstrated that efficacy and safety with TCZ-SC
were consistent with the established profile of TCZ-IV
[16!19]. The common-framework TOZURA study pro-
gramme comprised 11 separate protocols that enrolled
patients with RA in 22 countries [20]. TOZURA confirmed
the known efficacy and safety profile of TCZ-SC as mono-
therapy and in combination therapy in a pragmatic, phase
4 clinical setting [20].
Although GC therapy was permitted in the TCZ clinical
trials, data on the impact of GC use on the efficacy and
safety of TCZ-SC are limited. This post hoc analysis of
data from the TOZURA study programme evaluated the
efficacy and safety of TCZ-SC as monotherapy or in com-
bination with csDMARDs in subgroups of patients with RA
defined by baseline oral GC use.
Methods
Source data and study population
This post hoc analysis of data from TOZURA, a multina-
tional, open-label, single-arm, common-framework study
programme, comprised 11 protocols across 22 countries
(NCT01941940, NCT01941095, NCT01951170, NCT0-
1987479, NCT01988012, NCT01995201, NCT02001987,
NCT02011334, NCT02031471, NCT02046603, NCT0-
2046616). The common-framework study design ensured
that data collection methods and frequency were similar for
the first 24weeks of each individual study. Eligibility criteria,
study design and assessments for the TOZURA pro-
gramme have been previously described [20]. Briefly, the
study population comprised adult (aged 518years) pa-
tients with active RA as per the revised 1987 ACR or
2010 EULAR/ACR criteria. Patients had an inadequate re-
sponse to 51 csDMARD or 51 anti-TNF agent or were
MTX naı¨ve. All patients were TCZ naı¨ve at enrolment.
Previous bDMARD exposure was permitted, but
bDMARDs were prohibited during the study and were dis-
continued before TCZ-SC initiation. Patients received TCZ-
SC 162mg once weekly (qw) for 24weeks, administered at
investigator discretion as monotherapy or in combination
with a csDMARD. Stable concomitant csDMARDs (AZA,
chloroquine, HCQ, LEF, MTX or SSZ) were permitted
(54weeks before baseline) either alone or in combination,
except for the combination of MTX and LEF. Oral NSAIDs
and GCs (410mg/day prednisone or equivalent) were per-
mitted at a stable dose (54weeks before baseline). As per
the protocol, the GC dose was required to be stable during
the 24-week core study period and could be reduced only
for safety reasons. Efficacy and safety were evaluated
during the 24-week study period.
The TOZURA study protocols, amendments and
informed consent documentation were approved by the
respective local institutional review boards or independent
ethics committees of the investigational centres. All pa-
tients provided written, informed consent in accordance
with the Declaration of Helsinki.
Statistical analysis
Patients were categorized into four treatment subgroups
based on oral GC use at baseline: group 1—patients who
received TCZ-SC monotherapy and continued stable
baseline oral GC (monotherapy + GC subgroup); group
2—patients who received TCZ-SC monotherapy but no
oral GC (monotherapy without GC subgroup); group
3—patients who received TCZ-SC + csDMARD
combination therapy and continued stable baseline oral
GC (combination therapy + GC subgroup) and group
4—patients who received TCZ-SC + csDMARD combi-
nation therapy but no oral GC (combination therapy with-
out GC subgroup). Descriptive statistical methods were
used to summarize baseline characteristics, efficacy and
safety in treatment subgroups.
Assessments and outcomes
Efficacy end points were analysed over 24weeks in each
subgroup, including the proportion of patients achieving clin-
ical remission based on DAS in 28 joints using ESR (DAS28-
ESR), change in DAS28-ESR, Functional Assessment of
Chronic Illness Therapy-Fatigue score, HAQ-Disability
Index (HAQ-DI), tender joint count in 28 joints, swollen joint
count in 28 joints, patient global assessment (PGA) of pain
visual analogue scale (VAS) score and PGA of disease ac-
tivity VAS score. AEs and serious AEs (SAEs) occurring
during the 24-week study period were analysed in each sub-
group and classified by the Medical Dictionary for
Regulatory Activities system organ class terms.
Results
Baseline characteristics in glucocorticoid treatment
subgroups
A total of 1804 patients were enrolled in the TOZURA
study programme. Of the 353 patients who received
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TCZ-SC monotherapy qw, 145 (41.1%) received oral
GC at baseline and 208 (58.9%) did not. Of the 1451 pa-
tients who received TCZ-SC qw with a concomitant
csDMARD, 730 (50.3%) had baseline GC use and 721
(49.7%) did not.
Baseline demographics and disease characteristics
were generally balanced between treatment subgroups,
except for exposure to previous RA treatments (Table 1).
Previous csDMARD exposure was less frequent and pre-
vious bDMARD exposure was more frequent in the mono-
therapy subgroups than in the combination therapy
subgroups. In patients who received TCZ-SC monother-
apy, prior MTX exposure was more frequent in the mono-
therapy + GC subgroup than in the monotherapy without
GC subgroup (37.9% vs 1.9%); however, MTX exposure
at baseline was more frequent in both combination ther-
apy treatment subgroups (561.7%) than in the monother-
apy groups. Patients in the monotherapy subgroups had
numerically longer mean RA duration compared with
patients in the combination therapy subgroups, and nu-
merically higher proportions of patients in the subgroups
receiving GCs were seropositive for either RF or ACPA
compared with patients in the subgroups not receiving
GCs. RA disease severity as measured by DAS28-ESR
was comparable at initial diagnosis and at the week 1
visit (range of mean DAS28-ESR across subgroups,
5.10!5.43 vs 5.57!5.92).
Baseline daily GC doses were similar between the
monotherapy + GC and combination therapy + GC sub-
groups (mean, 6.6mg vs 6.5mg; median, 5mg in both
subgroups), with 57.2% and 61.8% of patients receiving
45mg daily in the monotherapy + GC and combination
therapy + GC subgroups, respectively (Table 1). As
required by the protocol, the majority (>96%) of patients
in the subgroups receiving GC remained on their baseline
GC dose during the 24-week study period.
TABLE 1 Baseline demographics and disease characteristics
Characteristics
TCZ-SC monotherapy TCZ-SC + csDMARD
GC use
(n=145)
No GC use
(n=208)
GC use
(n=730)
No GC use
(n=721)
Age, mean (S.D.), years 55.0 (12.7) 54.9 (12.7) 53.5 (12.7) 54.3 (11.6)
Sex, n (%)
Male 26 (17.9) 32 (15.4) 138 (18.9) 136 (18.9)
Female 119 (82.1) 176 (84.6) 592 (81.1) 858 (81.1)
Race, n (%)a
White 139 (95.9) 203 (97.6) 647 (88.6) 664 (92.1)
Black 3 (2.1) 1 (0.5) 27 (3.7) 26 (3.6)
Asian 0 1 (0.5) 8 (1.1) 6 (0.8)
American Indian or Alaska Native 0 1 (0.5) 0 0
Native Hawaiian or other Pacific Islander 0 0 0 0
Other 2 (1.4) 1 (0.5) 43 (5.9) 24 (3.3)
Weight, mean (S.D.), kg 69.2 (14.5) 74.1 (18.1) 71.6 (15.5) 74.4 (16.6)
RA duration, mean (S.D.), years 8.7 (8.0) 8.2 (8.4) 7.4 (7.6) 7.8 (8.3)
Seropositivity, n (%)
RFb 104 (77.6) 133 (68.9) 506 (74.6) 465 (70.7)
ACPAc 93 (77.5) 106 (63.5) 454 (73.9) 399 (68.2)
Evidence of structural joint damage, n (%)d 81 (61.4) 91 (52.6) 275 (43.7) 276 (45.0)
CRP, mean (S.D.), mg/l 21.0 (24.6) 15.3 (24.7) 16.1 (21.6) 12.6 (20.1)
DAS28-ESR at time of initial RA diagnosis, mean (S.D.) 5.39 (1.30) 5.34 (1.25) 5.43 (1.29) 5.10 (1.17)
DAS28-ESR at week 1 (baseline) visit, mean (S.D.) 5.92 (1.12) 5.79 (1.11) 5.93 (1.16) 5.57 (1.17)
Prednisone equivalent daily dose, mean (S.D.)
[median], mg
6.6 (2.9) [5] 0 6.5 (4.2) [5]e 0
Previous RA treatment exposure, n (%)
MTX 55 (37.9) 4 (1.9) 487 (66.7) 445 (61.7)
csDMARD (excluding MTX) 2 (1.4) 3 (1.4) 88 (12.1) 113 (15.7)
bDMARD 51 (35.2) 60 (28.8) 117 (16.0) 120 (16.6)
Medical history, any disease, n (%) 127 (87.6) 171 (82.2) 587 (80.4) 582 (80.7)
Vascular disorders 44 (30.3) 62 (29.8) 246 (33.7) 201 (27.9)
Musculoskeletal and connective tissue disorders 44 (30.3) 16 (7.7) 198 (27.1) 61 (8.5)
Gastrointestinal disorders 34 (23.4) 27 (13.0) 121 (16.6) 135 (18.7)
Infections and infestations 25 (17.2) 26 (12.5) 113 (15.5) 106 (14.7)
an = 144, 207, 726 and 720, respectively. bn = 134, 193, 678 and 658, respectively. cn = 120, 167, 614 and 585, respectively.
dn = 132, 173, 629 and 614, respectively. en = 725. In the combination therapy group, five patients were receiving GC at
baseline, but dose information was not available. bDMARD: biologic DMARD; csDMARD: conventional synthetic DMARD;
DAS28-ESR: DAS in 28 joints using ESR; GC: glucocorticoid; TCZ-SC: subcutaneous tocilizumab.
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Some expected differences between the GC and non-
GC subgroups were seen in baseline comorbidities
(Table 1). A history of vascular disorders, musculoskeletal
and CTDs or gastrointestinal disorders was more frequent
in the GC-exposed patients than in patients without GC
use, with the largest apparent differences in the preva-
lence of hypertension, osteoporosis and gastritis. A his-
tory of infections and infestations was found in similar
proportions of patients across treatment subgroups; the
most frequently reported types were latent tuberculosis,
herpes zoster, pneumonia and urinary tract infection.
Efficacy by treatment subgroups
The proportion of patients in DAS28-ESR!defined clinical
remission (DAS28-ESR <2.6) increased over 24weeks of
TCZ-SC treatment, with similar trends observed across all
four treatment subgroups (Fig. 1A and B). The proportion
of patients in clinical remission in the monotherapy with-
out GC subgroup was slightly lower across visits com-
pared with the monotherapy + GC subgroup. In each
treatment subgroup, the majority of patients had achieved
clinical remission at week 24. The reduction in mean
DAS28-ESR (Supplementary Fig. S1, available at
Rheumatology online) over 24weeks reflected these
trends. Upon evaluation of the impact of GC use on the
DAS28 domains, a trend towards a slightly greater numer-
ical decrease from baseline was apparent only for tender
joint count in 28 joints and swollen joint count in 28 joints
with GC use in both TCZ-SC groups (Fig. 1C!F).
In all treatment subgroups, the mean Functional
Assessment of Chronic Illness Therapy-Fatigue score
improved over the first 8weeks of TCZ-SC treatment and
remained stable through the week 24 visit (Fig. 2). Mean
HAQ-DI scores decreased over 24 weeks of TCZ-SC treat-
ment, with similar trends across subgroups; the largest im-
provement was observed in the weeks following treatment
initiation (Fig. 3). Mean PGA of pain and PGA of disease ac-
tivity VAS scores also decreased similarly in all treatment
groups from week 1 to week 12 and remained stable through
week 24 in all treatment subgroups (Supplementary Figs S2
and S3, available at Rheumatology online).
Safety by treatment subgroups
AEs were reported in 75.9!86.3% of patients with RA who
received TCZ-SC across treatment subgroups (Table 2),
with AEs reported in 81.6% and 85.5% of patients in the
GC and non-GC subgroups, respectively. The AE profiles
across treatment subgroups were largely similar, but had
some minor numerical differences. The most common AEs
by the Medical Dictionary for Regulatory Activities system
organ class terms were infections and infestations (range
across subgroups, 40.0-45.2%), investigations (primarily
laboratory investigations; 14.5!27.6%), gastrointestinal dis-
orders (18.6!26.2%) and musculoskeletal and CTDs
(18.3!22.3%) (Table 2). Laboratory abnormalities were
more frequent in the combination therapy subgroups than
in the monotherapy subgroups. Gastrointestinal disorders,
skin and subcutaneous tissue disorders and general dis-
orders and administration site conditions were less
frequent, and metabolism and nutrition disorders were
more frequent, in the GC subgroups than in the non-GC
subgroups.
Compared with patients experiencing any AE, only a
minor proportion of all patients experienced SAEs. SAEs
were reported in the monotherapy group in 13 patients
(9.0%) with GC use and in 16 (7.7%) without GC use; in
the combination therapy group, SAEs were reported in 42
patients (5.8%) with GC use and in 34 (4.7%) without GC
use (Supplementary Table S1, available at Rheumatology
online). The most frequently reported SAEs by body
system were infections and infestations (range across
subgroups, 1.1!2.1%), gastrointestinal disorders
(0.5!1.4%) and vascular disorders (0.1!2.1%). The fre-
quency of SAEs by body system was generally similar
across treatment subgroups with some slight numerical
differences between the combined GC use subgroups
[55 of 875 patients (6.3%)] vs the combined non-GC sub-
groups [50 of 929 patients (5.4%)]. These slight differ-
ences appear to be driven by differences in the number
of SAE infections (7 patients vs 2) and vascular disorders
(8 vs 2) in the combined GC use vs non-GC subgroups.
Discussion
This post hoc analysis of data from the phase 4 TOZURA
study programme examined the efficacy and safety of
TCZ-SC monotherapy and TCZ-SC in combination with
csDMARDs in subgroups of patients defined by baseline
GC use. The proportions of TCZ-SC!treated patients who
achieved clinical remission (DAS28-ESR < 2.6) were com-
parable across treatment subgroups. The AE profiles were
generally similar between treatment subgroups.
In the only similar study of another targeted DMARD
published to date, pooled data from six clinical trials of
tofacitinib in RA found no significant effect on the efficacy
of tofacitinib in patients with GC use compared with pa-
tients without GC use, with some slight differences be-
tween patients with and without concomitant csDMARD
use [6]. Consistent with the findings of the current evalu-
ation, an analysis of pooled data from four clinical trials of
TCZ-IV in patients with RA found no evidence that con-
comitant GC therapy affected the proportion of patients
who achieved DAS28-ESR!defined remission [21].
Although concomitant GC use did not appear to affect
the efficacy of TCZ-SC, a slight numerical trend toward
better control of disease activity by DAS28-ESR compos-
ite score was observed with GC use in patients who
received TCZ-SC monotherapy, but this trend was not
visible in the TCZ-SC + csDMARD subgroups, possibly
due to overlapping effects of csDMARDs and GCs.
When evaluating the impact of GC use on the DAS28 do-
mains, a trend toward a slightly higher numerical decrease
(1 joint) from baseline was apparent only for tender joint
count in 28 joints and swollen joint count in 28 joints with
GC use in both TCZ-SC groups. One could hypothesize
that, in line with the suggestions published recently, the
clinical domains of the DAS28 composite score are more
sensitive to detecting anti-inflammatory DMARD effects
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compared with the overall composite score, which in-
cludes psychological determinants of PGA [22].
The patient-reported outcomes were largely similar be-
tween the GC and non-GC subgroups; only HAQ-DI, PGA
of disease activity VAS and, to a lesser degree, PGA of
pain VAS appeared to reflect the subtle numerical trends
in disease activity and inflammation control observed
between these subgroups, with no apparent difference
in Functional Assessment of Chronic Illness Therapy-
Fatigue scores. These findings should be interpreted
cautiously due to the known—and probably un-
known—differences in disease characteristics between
patients with and without GC use. Of note, patients who
received GC treatment in TOZURA had longer duration of
FIG. 1 Efficacy of TCZ-SC over 24weeks in subgroups of patients with RA treated with TCZ-SC
Percentage of patients in clinical remission (DAS28-ESR <2.6) over 24weeks in subgroups of patients with RA treated
with (A) TCZ-SC monotherapy or (B) TCZ-SC + csDMARD. TJC28 over 24weeks in subgroups of patients with RA treated
with TCZ-SC in subgroups of patients with RA treated with (C) TCZ-SC monotherapy or (D) TCZ-SC + csDMARD. SJC28
over 24weeks in subgroups of patients with RA treated with (E) TCZ-SC monotherapy or (F) TCZ-SC + csDMARD.
csDMARD: conventional synthetic DMARD; DAS28-ESR: DAS in 28 joints using ESR; GC: glucocorticoid; SJC28: swollen
joint count in 28 joints; TCZ-SC: subcutaneous tocilizumab; TJC28: tender joint count in 28 joints.
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RA and slightly higher disease activity, and a greater pro-
portion of GC-treated patients were RF or ACPA seroposi-
tive compared with patients in the non-GC subgroups.
Somewhat more patients in the non-GC subgroups
experienced non-serious AEs than patients in the GC sub-
groups. Similarly, some slight numerical differences were
observed between GC and non-GC subgroups in SAEs,
particularly infections and vascular disorders. On the
basis of the available information, these minor differences
cannot be explained in a robust scientific way, but a
slightly increased risk of GC-associated AEs cannot be
excluded. However, notably, in CAPRA-2, a 12-week ran-
domized, double-blind, placebo-controlled study of pred-
nisone 5mg/day in patients with RA, the frequency of any
AE was somewhat lower in 231 patients treated with pred-
nisone than in 119 patients who received placebo (42.9%
vs 48.7%) [23].
This analysis has several limitations. This was a post
hoc analysis of the TOZURA study programme, which
was not designed to compare the efficacy and safety in
subgroups based on GC use; hence, any conclusions
should be treated as exploratory. This analysis does not
allow for any conclusions regarding the efficacy of GCs in
RA; it allows for the generation of hypotheses regarding
whether prior and continuing stable concomitant low-
dose GC use is associated with any impact on the efficacy
and safety of TCZ-SC in patients with active RA. This
study only included patients who received TCZ-SC
weekly; patients receiving TCZ-SC every 2weeks or
TCZ-IV once every 4weeks may not exhibit the same
trends in efficacy and safety with GC use vs without GC
use. Also, potential effects arising from differences in
GC dose were not evaluated. Additionally, patients in
the GC subgroups had prior exposure to GC; thus,
FIG. 2 FACIT-F score over 24weeks in subgroups of patients with RA treated with (A) TCZ-SC monotherapy or (B) TCZ-
SC + csDMARD
csDMARD: conventional synthetic DMARD; FACIT-F: Functional Assessment of Chronic Illness Therapy-Fatigue; GC:
glucocorticoid; TCZ-SC: subcutaneous tocilizumab.
FIG. 3 HAQ-DI score over 24weeks in subgroups of patients with RA treated with (A) TCZ-SC monotherapy or (B) TCZ-
SC + csDMARD
csDMARD: conventional synthetic DMARD; GC: glucocorticoid; HAQ-DI: HAQ-Disability Index; TCZ-SC: subcutaneous
tocilizumab.
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these patients were less likely to experience an AE due to
GC use. Further, the follow-up was limited to 24weeks as
per the common-framework protocol used across substu-
dies and did not permit the observation of long-term ef-
fects in this pooled analysis. This limitation is notable
when considering the burden of comorbidities associated
with long-term GC use, including infections, cardiovascu-
lar disease, osteoporosis and diabetes, in patients with
RA [3,24]. Potential effects of concomitant medications
used to treat comorbid conditions were not evaluated.
Despite a large sample size in the phase 4 setting, the
population of the common-framework TOZURA study
programme was likely less heterogeneous than the popu-
lations of pooled analyses of multiple clinical trials [6,21].
In this post hoc analysis of a large RA cohort treated with
TCZ-SC in a phase 4 clinical setting, GC use did not appear
to impact the efficacy of introducing TCZ-SC as monother-
apy or in combination with concomitant csDMARDs. Similar
safety profiles for TCZ-SC as monotherapy and in combin-
ation with csDMARDs were observed over 24weeks in pa-
tients with or without background GC treatment, though
some slight numerical differences were observed between
patients receiving GC and those without.
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TABLE 2 Summary of AEs over 24weeks in subgroups of patients with RA treated with TCZ-SC
Patients with 51 AE by body system, n (%)
TCZ-SC monotherapy TCZ-SC + csDMARD
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No GC use
(n=208)
GC use
(n=730)
No GC use
(n=721)
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Skin and subcutaneous tissue disorders 25 (17.2) 41 (19.7) 98 (13.4) 146 (20.2)
Nervous system disorders 17 (11.7) 23 (11.1) 70 (9.6) 113 (15.7)
Respiratory, thoracic and mediastinal disorders 21 (14.5) 26 (12.5) 78 (10.7) 98 (13.6)
Blood and lymphatic system disorders 9 (6.2) 19 (9.1) 77 (10.5) 93 (12.9)
Injury, poisoning and procedural complications 12 (8.3) 15 (7.2) 68 (9.3) 76 (10.5)
Vascular disorders 8 (5.5) 19 (9.1) 57 (7.8) 51 (7.1)
Metabolism and nutrition disorders 10 (6.9) 10 (4.8) 52 (7.1) 32 (4.4)
Eye disorders 9 (6.2) 11 (5.3) 18 (2.5) 34 (4.7)
Psychiatric disorders 6 (4.1) 9 (4.3) 30 (4.1) 21 (2.9)
Reproductive system and breast disorders 0 5 (2.4) 15 (2.1) 25 (3.5)
Renal and urinary disorders 2 (1.4) 1 (0.5) 21 (2.9) 18 (2.5)
Cardiac disorders 5 (3.4) 8 (3.8) 15 (2.1) 13 (1.8)
Hepatobiliary disorders 1 (0.7) 5 (2.4) 17 (2.3) 16 (2.2)
Surgical and medical procedures 5 (3.4) 8 (3.8) 14 (1.9) 6 (0.8)
Ear and labyrinth disorders 3 (2.1) 3 (1.4) 7 (1.0) 18 (2.5)
Neoplasms benign, malignant and unspecified
(including cysts and polyps)
0 2 (1) 9 (1.2) 16 (2.2)
Immune system disorders 0 0 11 (1.5) 13 (1.8)
Endocrine disorders 1 (0.7) 1 (0.5) 1 (0.1) 2 (0.3)
Congenital, familial and genetic disorders 0 0 4 (0.5) 0
aOf the 508 investigations AEs reported, 501 were laboratory investigations and 7 were not; these exceptions included cardiac
murmur (3 events), colposcopy (1), breath sounds (1), heart rate irregular (1) and heart rate increased (1). AE: adverse event;
csDMARD: conventional synthetic DMARD; GC: glucocorticoid; TCZ-SC: subcutaneous tocilizumab.
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